Journal
AMERICAN JOURNAL OF SURGERY
Volume 218, Issue 1, Pages 164-169Publisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjsurg.2018.12.058
Keywords
T1 esophageal cancer; Adenocarcinoma; Endoscopy; Endoscopic mucosal resection; Esophagectomy; Cost analysis; Outcomes
Categories
Funding
- Ryan Hill Research Foundation
Ask authors/readers for more resources
Background: Endoscopic therapy is considered to be comparable to esophagectomy with respect to oncologic outcomes in early (cT1) esophageal adenocarcinoma (EC). The current study aims to compare early outcomes and financial costs, associated with endoscopic versus surgical therapy for early esophageal adenocarcinoma. Methods: Retrospective review of patients undergoing either endoscopic or surgical therapy for cT1 EC between 2010 and 2015. Results: Age, BMI, and Charlson Comorbidity Scores were similar in patients undergoing endoscopic therapy (N = 20) and esophagectomy (N = 23). For patients undergoing endoscopic therapy a median of 6 endoscopic interventions, were performed per patient (range 2-18). Esophagectomy was associated with a median hospital stay of 9 (8-13) days and greater procedure specific morbidity compared to endoscopic therapy. Costs related to endoscopic therapy were significantly lower compared to esophagectomy ($22,640 vs. $53,849, P < 0.001). Conclusions: Endoscopic treatment is associated with decreased morbidity and financial costs when compared to esophagectomy. (C) 2019 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available